Biologics, Biosimilars and Diagnostics: IP Challenges for Early Stage Life Sciences Companies

Goodwin Procter will host a client seminar focused on the interplay between patent rights and regulatory exclusivities is particularly important for early stage life sciences companies focused on biologics and diagnostics. This comprehensive discussion of the various intellectual property and regulatory challenges facing early stage companies in today’s market include topics such as: patent eligibility and development of patent rights for biologics and diagnostics after Prometheus and Myriad cases, regulatory exclusivities for biologics/biosimilars, and the impact of safe harbor exceptions and patent rights on R&D. Goodwin Procter partners Theresa Kavanaugh and Elaine Herrmann Blais will be presenting.